Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and Letrozole in Neoadjuvant HR+ Breast Cancer
NCT04614194Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Apr 2021
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abemaciclib in breast cancer (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Change in T cell activation at 14 days. Started Apr 2021; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04614194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614194.